Value of Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in the Diagnosis of Ovarian Neoplasm in Young Adult Female.

Deepa Hatwal; Neha Batra; Chitra Joshi; Daulat Singh; Sheela Chaudhari; Haroon Ali S; Pawan Bhatt

Volume : IX, Issue : VI, June - 2020

Value of Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in the Diagnosis of Ovarian Neoplasm in Young Adult Female.

Deepa Hatwal, Neha Batra, Chitra Joshi, Daulat Singh, Sheela Chaudhari, Haroon Ali S, Pawan Bhatt

Abstract :

Background: Ovarian tumors at a young age are rare and reported to be 2% of all the cases seen. Relationship between poor prognosis of ovarian malignancies and changes in complete blood count parameter have been proposed previously. Objective: To determine the association among neutrophil to- lymphocyte ratio (NLR), Platelet –to-lymphocyte ratio (PLR), and ovarian tumour in young female adult. Method: A retrospective and prospective study was performed on 73 young females with ovarian masses. Two groups were constituted with respect to the clinical and histopathological results.Group 1, constitute Non neoplastic patients ( n=45); and Group 2, neoplastic patients ( n=28). The main parameters recorded from the hospital database and patients� files were age, haemoglobin, haematocrit, white blood cell count, absolute neutrophil, lymphocyte, platelet counts, and post operative histopathology result. Result: The Mean age of the patients in group 1 was 24.56�3.55, and in group 2 was 23.61�3.79. Abdominal pain was the most common presentation. Most common lesion in group 1 was Follicular cyst (55.33%) followed by Corpus luteal cyst ( 1.11%). Benign cystic teratoma (42.9%) was the most common neoplastic ovarian mass. Haemoglobin, Platelet count, neutrophil to lymphocyte ratio (NLR) and Platelet to lymphocyte ratio (PLR) were highly Significant in neoplastic lesion group than the non-neoplastic group.(p<.001) Conclusion:- Significant Value of NLR and PLR may predict ovarian neoplasm in young females and can be used for discrimination to cancer from pathologically normal patients even in primary setups.